



ASX Announcement

15 November 2024

2024 Annual General Meeting – Chairman’s Address

In accordance with ASX Listing Rule 3.13.3, Atomo Diagnostics Limited (**Atomo**) attaches the Chairman's Address to be delivered at Atomo's 2024 Annual General Meeting.

For more information, please contact:

John Kelly

Managing Director & CEO

e. john.kelly@atomodiagnostics.com

p. +61 401 922 279

This announcement was authorised by the Managing Director & CEO on behalf of the Board.



On behalf of my fellow directors, I welcome you warmly to Atomo Diagnostics' (Atomo) Annual General Meeting for 2024.

Our agenda starts with me talking about Atomo's financial year to June 30, 2024, and our current year to date. I will invite John Kelly, Atomo's CEO and Managing Director, to discuss both in further detail.

I will then ask you to consider several resolutions we have put forward. The Board highly values shareholder feedback and participation in our AGM.

The Board is particularly mindful of the Resolution concerning Remuneration, which received a strike at our last AGM. Reflecting shareholder feedback, you will see that this year's Resolution on Remuneration is materially different. I will spend time on this when we reach Resolutions.

Your Company continues to participate extensively in the adoption of rapid testing as a critical means of early infection detection. Advocacy for such testing is shared with the Federal Government amongst public and private agencies globally. Locally, such support sees the Federal Government funding free distribution of Atomo's HIV self-test through vending machines.

Decentralised testing serves to empower and scale. Individuals are empowered through having user-friendly devices that test for specific conditions with immediate results. Similarly, decentralised testing settings screen effectively and early, scaling the health system's capacity to respond to community health needs.

Throughout last financial year and so far this year, we have seen the continuing adoption of rapid tests by both consumers and professional users. With our partner Newfoundland Healthcare, Atomo's tests are on the shelves of TESCO and Boots, while through our direct sales, you can find our tests in local pharmacies and through vending machines care of a Federal funded scheme.

Our revenue comprises sales of finished products led by our HIV tests, self-test and for professional use. Sales of our platforms under OEM+ contracts serve to scale Atomo's technologies across different tests, including LUMOS' FebriDX's bacterial test and NG Biotech's pregnancy test.

Looking ahead, we announced a Federal Government grant for Atomo to support the development of the world's first rapid test for detection of active syphilis in collaboration with the Burnett Institute. We are also delighted with BARDA's announced support for LUMOS' Pascal based FebriDx to seek a CLIA waiver to allow widespread distribution in the US.

For those who are more recent Atomo shareholders, our warm welcome. Let me summarise what we do in rapid diagnostics.

Atomo develops, commercialises, and supplies finished rapid diagnostic tests and devices for rapid diagnostic tests. We also partner with clinical partners to develop new tests and launch them into global markets. Our technology supports testing to detect infectious diseases, chronic health conditions, and consumer wellness.

Atomo participates in three identified markets in developing and commercialising diagnostic devices. These comprise infectious disease testing, OEM+ devices, and sexual health and wellness.



Each of these markets involves Atomo's scale deployment of our patented technologies, often through partnering.

Atomo's HIV Test leads our work in infectious diseases. Demand spans Global Health Programmes and increasingly developed consumer markets. We extend across B2B sales in our OEM business and B2C through direct and partnered sales. As an example, we are delighted to have our HIV Self-Test supplied through Tesco Supermarkets and Boots pharmacies in the UK

In global health, our continuing relationship with Viatris Inc. sees growing in-country approvals for the sale of our HIV tests, especially amongst developing countries. As partners, during the year, we supplied Atomo platform devices to NG Biotech, Access Biotech, and Lumos Diagnostics to house support their proprietary clinical rapid diagnostic tests.

Turning to our financial management, I mentioned that Atomo's change in year-on-year revenues and sales mix reflected the overall market demand reduction with the pandemic passing. Our corresponding ramp-up is in the production and delivery of our patented products.

The Board and Executives exercise appropriate care in financial management, prioritising revenue growth and judicious regard for spending. The latter is focused very much on supporting the promotion and delivery of existing Atomo products. We continue to work with the Company to ensure efficiency and benefit from reduced operating costs, including reduced Board costs. John will talk through these changes.

To this end, the Board very much acknowledges the considerable efforts across the Executive team and the wider Atomo workplace to seek efficiency in our activities. I am pleased to report that these efforts are underway, and concurrently, we see strong positive employee engagement through our workplace surveys.

On behalf of Atomo's Board and Management, we gratefully acknowledge the tireless efforts of those who provide services and advice to Atomo – George Sidis and Richard Sokolov at IDE. Mathew Watkins and Kiara Ferraro, who provide Company Secretary services through Vistra Australia, and Gareth Few of BDO.

Atomo's Board of Directors shares substantial commercial, governance, and industry experience across the critical aspects of our business. Among the Board's priorities is ensuring we have the capabilities and domain expertise to govern our global business effectively.

Our Board comprises Deborah Neff, Dr Paul Kasian, Dr Cher Walker, John Kelly, and me. Deborah chairs our People, Culture, and Remuneration Committee, and Paul chairs Audit and Risk, which are pillars of our corporate governance. I sit on both Committees.

In keeping with Atomo's board process, you will shortly be asked to consider Deborah for re-election to the Board. Along with fellow Directors and Executives, I value Deborah's contribution greatly and strongly endorse her re-election.

In closing, I share the Board's strong recognition of the Atomo team's commitment to developing and implementing the Company's strategy while making sense of and realising new opportunities.



The decentralisation of health services, diagnostics and care continues to evolve. The adoption of rapid diagnostics has changed users' behaviours and expectations of testing by location, speed to results and timelier prescription. These changes align with Atomo's proven competencies and focus on developing tests addressing unmet consumer needs. Atomo's competitive positioning draws from our product and commercialisation expertise. We are excited about this year and those ahead. I welcome John to talk about what we are up to in further detail. Thank you for your enthusiastic support, questions, and interest in Atomo.